Yaşlı Hastalarda Aşırı Aktif Mesane Tedavisinde Mirabegron Tedavisinin Oküler ve Sistemik Güvenliği

Amaç: Yaşlı hastalarda aşırı aktif mesane (AAM) tedavisinde mirabegron tedavisinin sistemik ve oküler güvenliğini test etmeyi amaçladık. Yöntemler: Çalışmaya üroloji kliniğine başvuran ve aşırı aktif mesane semptomları olan 34 kadın, 40 erkek toplam 74 hasta dahil edildi. 60 yaş üzeri hastalar alındı, ortalama yaş 69.48±7.8 saptandı. Günlük 50 mg mirabegron verildi. Hastalar 3 ay takip edildi. Hastaların tedavi öncesi ve sonrası; semptom skoru, sağ göz ve sol göz intraoküler basınçları (İOB), sistolik ve diastolik kan basıncı değerleri kaydedildi. 3. ayın sonundaki değerler ile tedavi öncesi değerler karşılaştırıldı. İkili hipertansif ilaç kullanan ve tansiyon değeri 155/95' in üzerinde olan hastalar çalışma dışı bırakıldı. Bulgular: Semptom skoru tedavi öncesi 18.67±9.87 saptanırken, 3 aylık tedavi sonrasında 9.83±2.71 saptandı (p=0.0001). Sağ göz IOB değerleri tedavi öncesi 16.06±2.62 mmHg iken tedavi sonrası 15.85±2.31 mmHg saptandı (p=0.341). Sol göz IOB değerleri tedavi öncesi 15.96±2.35 mmHg iken tedavi sonrası 15.94±2.21 mmHg saptandı (p=0.855). Sistolik kan basıncı değerleri tedavi öncesi 128.91±11.76 mmHg iken tedavi sonrası 128.43±11.95 mmHg saptandı (p=0.110). Diastolik kan basıncı değerlerine bakıldığında tedavi öncesi 81.94±9.83 mmHg iken tedavi sonrası 81.31±10.14 mmHg saptandı (p=0.071). Sonuç: Yaşlı hastalarda aşırı aktif mesane tedavisinde oral mirabegron 50 mg/gün kullanımı IOB' ı arttırmamaktadır. Genel olarak güvenli ve iyi tolere edilebilen bir tedavidir.

Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder

Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactivebladder in elderly patients.Method: A total of 74 patients (40 male, 34 female) with symptoms of overactive bladder admitted to the urologyclinic were included in the study. Patients over 60 years old were included. Patients were followed-up for 3 months.Symptom scores (according to OAB-V8 form), intraocular pressure (IOP) readings of right and left eyes, systolic anddiastolic blood pressures of the patients were recorded before and after the treatment. At the end of 3 months, allvalues were re-evaluated and compared with pre-treatment data.Results: Mean age was 69.48±7.8 years. The symptom score was found to be 18.67 ± 9.87 before the treatment and9.83 ± 2.71 after 3 months of the treatment (p=0.0001). Right eye mean IOP value was 16.06 ± 2.62 mmHg beforetreatment and 15.85 ± 2.31 mmHg after treatment (p=0.341). Left eye mean IOP value was 15.96±2.35 mm mmHgbefore treatment and 15.94±2.21 mm after treatment (p=0.855). Systolic blood pressure measurements were128.91±11.76 mmHg before treatment and 128.43±11.95 mmHg after the treatment (p=0.110). Diastolic bloodpressure measurements were 81.94±9.83 mmHg before the treatment and 81.31±10.14 mmHg after the treatment(p=0.071).Conclusion: Treatment of overactive bladder with mirabegron 50mg/day is well tolerated and safe in elderly patients.

PDF

___

1. Chapel CR, Amarenco G, Lopez Aramburu MA, et all. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013; 32: 1116-22.
2. Thiagamoorthy G, Kotes S, Zacche M, et all. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. TherAdv Urol 2016; 8: 38-46.
3. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
4. Tarcan T, Mangır N, Özgür MÖ, et all. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni 2012; 21: 113-16.
5. Geyer O, Bar-Ilan, A., Nachman, R, et all. Beta3- adrenergic relaxation of bovine iris sphincter. FEBS Lett 1998; 429: 356–8.
6. Diebold Y, Rios J.D, Hodges R.R, et all. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest. Ophthalmol. Vis. Sci 2001; 42: 2270–82.
7. Mori A, Miwa T, Sakamoto K, et all. Pharmacological evidence for the presence of functional ocular safety of mırabegron ın healthy volunteers 679 beta (3)- adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 119– 126.
8. Steinle J.J, Zamora D.O, Rosenbaum J.T, Granger H.J. Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp. Eye Res 2005; 80: 83–91.
9. Lee C-L, Kuo H-C. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Lower Urinary Tract Symptoms 2019; 11: 93- 97.https://doi.org/10.1111/luts.12224.
10. Gray SL, Anderson ML, Dublin S, et all. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175: 401–7.
11. Chapple C, DuBeau C, Ebinger U, et all. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12- week trial. Curr Med Res Opin 2007 ; 23:2347–58.
12. Wagg A, Arumi D, Herschorn S, et all. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing 2017; 46: 620–6.
13. Chapple CR, Kaplan SA, Mitcheson D, et all. Randomized doubleblind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β (3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.
14. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987–1006.
15. Sung VC, Corridan PG. Acute-angle closure glaucoma as a sideeffect of oxybutynin. Br J Urol 1998; 81: 634–5.
16. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
17. Turkoglu AR, Yener NP, Coban S, Guzelsoy M, Demirbas M, Demirci H. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Int Urogynecol J 2017; 28: 777-81. doi: 10.1007/s00192-016-3199-x. Epub 2016 Nov 14.
18. Garely AD, Kaufman JM, Sand PK, et all. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). ClinTher 2006; 28: 1935–46.
19. Nambiar AK, Bosch R, Cruz F, et all. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol 2018; 73: 596-609. Doi: 10.1016/j.eururo.2017.12.031. Epub 2018 Feb 3.